Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2010

01.10.2010

Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro

verfasst von: Kiran Kumar R. Mangalpally, Alan Siqueiros-Garcia, Muthiah Vaduganathan, Jing-Fei Dong, Neal S. Kleiman, Sasidhar Guthikonda

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Circulating platelets are heterogeneous in size and structure. Whether this translates into differences in platelet function and efficacy of antiplatelet therapy is unclear. Hence, we decided to investigate the activation patterns among different platelet populations differentiated by size, and to compare the inhibitory effects of aspirin in these populations. Circulating platelets from 9 healthy volunteers were separated by size and stratified into the largest and smallest quintiles. Platelets were stimulated with 75 μM arachidonic acid (AA), 10 μM ADP or 25 μM TRAP. Alpha-granule protein secretion and expression (P-selectin, VWF, fibrinogen), surface-protein activation (activated integrin αIIbβ3) were assessed. Platelet thromboxane B2 (TxB2) synthesis following AA stimulation was measured in vitro before and after incubation with 265 μM aspirin. Reticulated (juvenile) platelets were assessed using thiazole orange staining. A greater number of large platelets in the largest quintile were reticulated compared with the smallest quintile (6.1 ± 2.8% vs. 1.2 ± 1.5% respectively, p < 0.001). Larger platelets also synthesized more TxB2 than small platelets both before (1348 ± 276 pg/mL vs. 1023 ± 214 pg/mL, respectively, p = 0.01) and after aspirin (1029 ± 190 pg/mL vs. 851 ± 159 pg/mL, respectively, p = 0.03). After stimulation with each agonist, a greater proportion of large platelets bound fibrinogen, VWF, P-selectin and activated integrin αIIbβ3 than small platelets both in the presence and in the absence of in vitro aspirin. In an in vitro setting, large platelets appear to be more active than small platelets and continue to be more active even after in vitro aspirin.

Condensed Abstract

Platelets exhibit heterogeneity in size and structure. Whether this translates into platelet function and efficacy of antiplatelet therapy is unclear. We evaluated platelet functional properties and the effects of aspirin on separated platelet subpopulations in an in vitro setting. Platelets were sorted into the largest and smallest size quintiles using flow cytometry forward scatter. Alpha-granule protein release, dense granule content, surface protein activation and thromboxane synthesis were significantly greater in large platelets compared with small platelets, before and after stimulation with arachidonic acid, ADP and TRAP. Even after incubation with aspirin, large platelets continued to be more active than small platelets. In conclusion, large platelets are more active than small platelets and aspirin fails to eliminate these differential activation properties.
Literatur
1.
Zurück zum Zitat Karpatkin S (1969) Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 48(6):1073–1082CrossRefPubMed Karpatkin S (1969) Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 48(6):1073–1082CrossRefPubMed
2.
Zurück zum Zitat Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 48(6):1083–1087CrossRefPubMed Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 48(6):1083–1087CrossRefPubMed
3.
Zurück zum Zitat Bancroft AJ et al (2000) Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 11(7):379–387CrossRefPubMed Bancroft AJ et al (2000) Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 11(7):379–387CrossRefPubMed
4.
Zurück zum Zitat Pizzulli L et al (1998) Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 19(1):80–84CrossRefPubMed Pizzulli L et al (1998) Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 19(1):80–84CrossRefPubMed
5.
Zurück zum Zitat Endler G et al (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117(2):399–404CrossRefPubMed Endler G et al (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117(2):399–404CrossRefPubMed
6.
Zurück zum Zitat Khandekar MM et al (2006) Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 59(2):146–149CrossRefPubMed Khandekar MM et al (2006) Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 59(2):146–149CrossRefPubMed
7.
Zurück zum Zitat Yang A, Pizzulli L, Luderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117(4):371–377CrossRefPubMed Yang A, Pizzulli L, Luderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117(4):371–377CrossRefPubMed
8.
Zurück zum Zitat Greisenegger S et al (2004) Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 35(7):1688–1691CrossRefPubMed Greisenegger S et al (2004) Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 35(7):1688–1691CrossRefPubMed
9.
Zurück zum Zitat Bath P et al (2004) Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35(3):622–626CrossRefPubMed Bath P et al (2004) Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35(3):622–626CrossRefPubMed
10.
Zurück zum Zitat Choudhury A et al (2007) Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 49(19):1957–1964CrossRefPubMed Choudhury A et al (2007) Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 49(19):1957–1964CrossRefPubMed
11.
Zurück zum Zitat Papanas N et al (2004) Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 15(8):475–478CrossRefPubMed Papanas N et al (2004) Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 15(8):475–478CrossRefPubMed
12.
Zurück zum Zitat Tavil Y et al (2007) Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120(2):245–250CrossRefPubMed Tavil Y et al (2007) Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120(2):245–250CrossRefPubMed
13.
Zurück zum Zitat Collaborative Overview of Randomised Trials of Antiplatelet Therapy–I (1994) Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ 308(6921):81–106 Collaborative Overview of Randomised Trials of Antiplatelet Therapy–I (1994) Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ 308(6921):81–106
14.
Zurück zum Zitat Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71(5):397–403CrossRefPubMed Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71(5):397–403CrossRefPubMed
15.
Zurück zum Zitat Gum PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965CrossRefPubMed Gum PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965CrossRefPubMed
16.
Zurück zum Zitat Eikelboom JW et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14):1650–1655CrossRefPubMed Eikelboom JW et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14):1650–1655CrossRefPubMed
17.
Zurück zum Zitat Krasopoulos G et al (2008) Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336(7637):195–198CrossRefPubMed Krasopoulos G et al (2008) Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336(7637):195–198CrossRefPubMed
18.
Zurück zum Zitat Guthikonda S et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5(3):490–496CrossRefPubMed Guthikonda S et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5(3):490–496CrossRefPubMed
19.
Zurück zum Zitat Guthikonda S et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52(9):743–749CrossRefPubMed Guthikonda S et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52(9):743–749CrossRefPubMed
20.
Zurück zum Zitat Thompson CB et al (1984) Platelet size and age determine platelet function independently. Blood 63(6):1372–1375PubMed Thompson CB et al (1984) Platelet size and age determine platelet function independently. Blood 63(6):1372–1375PubMed
21.
Zurück zum Zitat Morigi M et al (2001) Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 98(6):1828–1835CrossRefPubMed Morigi M et al (2001) Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 98(6):1828–1835CrossRefPubMed
22.
Zurück zum Zitat Wall JE et al (1995) A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89(2):380–385CrossRefPubMed Wall JE et al (1995) A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89(2):380–385CrossRefPubMed
23.
Zurück zum Zitat Balint B et al (2002) Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap) 32(4):363–375 Balint B et al (2002) Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap) 32(4):363–375
24.
Zurück zum Zitat Bakovic D et al (2009) Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol 36(4):441–446CrossRefPubMed Bakovic D et al (2009) Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol 36(4):441–446CrossRefPubMed
25.
Zurück zum Zitat Chamberlain KG et al (1989) The relationship of human platelet density to platelet age: platelet population labeling by monoamine oxidase inhibition. Blood 73(5):1218–1225PubMed Chamberlain KG et al (1989) The relationship of human platelet density to platelet age: platelet population labeling by monoamine oxidase inhibition. Blood 73(5):1218–1225PubMed
26.
Zurück zum Zitat Jaremo P et al (2009) Elevated platelet density and enhanced platelet reactivity in stable angina pectoris complicated by diabetes mellitus type II. Thromb Res 124(3):373–374CrossRefPubMed Jaremo P et al (2009) Elevated platelet density and enhanced platelet reactivity in stable angina pectoris complicated by diabetes mellitus type II. Thromb Res 124(3):373–374CrossRefPubMed
27.
Zurück zum Zitat Apelseth TO, Hervig T (2007) In vitro evaluation of platelet concentrates during storage: platelet counts and markers of platelet destruction. Transfus Apher Sci 37(3):261–268CrossRefPubMed Apelseth TO, Hervig T (2007) In vitro evaluation of platelet concentrates during storage: platelet counts and markers of platelet destruction. Transfus Apher Sci 37(3):261–268CrossRefPubMed
28.
Zurück zum Zitat Boos CJ, Balakrishnan B, Lip GY (2008) The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. J Thromb Thrombolysis 25(2):135–140CrossRefPubMed Boos CJ, Balakrishnan B, Lip GY (2008) The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. J Thromb Thrombolysis 25(2):135–140CrossRefPubMed
29.
Zurück zum Zitat Milovanovic M et al (2003) Identification of low-density platelet populations with increased reactivity and elevated alpha-granule content. Thromb Res 111(1–2):75–80CrossRefPubMed Milovanovic M et al (2003) Identification of low-density platelet populations with increased reactivity and elevated alpha-granule content. Thromb Res 111(1–2):75–80CrossRefPubMed
30.
Zurück zum Zitat Jaremo P et al (2001) Inverse relationship between platelet density and reactivity alterations at coronary angiography. Haemostasis 31(1):55–60PubMed Jaremo P et al (2001) Inverse relationship between platelet density and reactivity alterations at coronary angiography. Haemostasis 31(1):55–60PubMed
31.
Zurück zum Zitat Jaremo P et al (2000) The use of platelet density and volume measurements to estimate the severity of pre-eclampsia. Eur J Clin Invest 30(12):1113–1118CrossRefPubMed Jaremo P et al (2000) The use of platelet density and volume measurements to estimate the severity of pre-eclampsia. Eur J Clin Invest 30(12):1113–1118CrossRefPubMed
32.
Zurück zum Zitat Jaremo P, Sandberg-Gertzen H (1996) Platelet density and size in inflammatory bowel disease. Thromb Haemost 75(4):560–561PubMed Jaremo P, Sandberg-Gertzen H (1996) Platelet density and size in inflammatory bowel disease. Thromb Haemost 75(4):560–561PubMed
33.
Zurück zum Zitat Noris P et al (2009) Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 7(12):2131–2136CrossRefPubMed Noris P et al (2009) Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 7(12):2131–2136CrossRefPubMed
34.
Zurück zum Zitat Kario K, Matsuo T, Nakao K (1992) Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 14(4):281–287CrossRefPubMed Kario K, Matsuo T, Nakao K (1992) Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 14(4):281–287CrossRefPubMed
35.
Zurück zum Zitat Coban E et al (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59(8):981–982CrossRefPubMed Coban E et al (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59(8):981–982CrossRefPubMed
36.
Zurück zum Zitat Nadar S, Blann AD, Lip GY (2004) Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 36(7):552–557CrossRefPubMed Nadar S, Blann AD, Lip GY (2004) Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 36(7):552–557CrossRefPubMed
37.
Zurück zum Zitat Pathansali R, Smith N, Bath P (2001) Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 12(5):292–297CrossRefPubMed Pathansali R, Smith N, Bath P (2001) Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 12(5):292–297CrossRefPubMed
38.
Zurück zum Zitat Braekkan SK et al (2009) Mean platelet volume is a risk factor for venous thromboembolism––the Tromso study. J Thromb Haemost 8(1):157–162CrossRefPubMed Braekkan SK et al (2009) Mean platelet volume is a risk factor for venous thromboembolism––the Tromso study. J Thromb Haemost 8(1):157–162CrossRefPubMed
39.
Zurück zum Zitat Packham MA et al (1989) Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 62(3):968–976PubMed Packham MA et al (1989) Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 62(3):968–976PubMed
40.
Zurück zum Zitat Lev EI et al (2007) Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol 99(1):124–128CrossRefPubMed Lev EI et al (2007) Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol 99(1):124–128CrossRefPubMed
41.
Zurück zum Zitat Smith SC Jr et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363–2372CrossRefPubMed Smith SC Jr et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363–2372CrossRefPubMed
Metadaten
Titel
Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro
verfasst von
Kiran Kumar R. Mangalpally
Alan Siqueiros-Garcia
Muthiah Vaduganathan
Jing-Fei Dong
Neal S. Kleiman
Sasidhar Guthikonda
Publikationsdatum
01.10.2010
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2010
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-010-0489-x

Weitere Artikel der Ausgabe 3/2010

Journal of Thrombosis and Thrombolysis 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.